Janus Henderson Group PLC Reduces Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Janus Henderson Group PLC lowered its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 8.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 233,950 shares of the company's stock after selling 22,497 shares during the quarter. Janus Henderson Group PLC's holdings in Takeda Pharmaceutical were worth $3,097,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the stock. Hudson Bay Capital Management LP grew its holdings in Takeda Pharmaceutical by 10.0% during the fourth quarter. Hudson Bay Capital Management LP now owns 275,000 shares of the company's stock worth $3,641,000 after buying an additional 25,000 shares in the last quarter. Focus Partners Wealth grew its holdings in Takeda Pharmaceutical by 431.7% during the fourth quarter. Focus Partners Wealth now owns 79,499 shares of the company's stock worth $1,054,000 after buying an additional 64,548 shares in the last quarter. Cornerstone Select Advisors LLC bought a new stake in Takeda Pharmaceutical during the fourth quarter worth $167,000. Cubist Systematic Strategies LLC bought a new stake in Takeda Pharmaceutical during the fourth quarter worth $5,915,000. Finally, Cetera Investment Advisers grew its holdings in Takeda Pharmaceutical by 14.7% during the fourth quarter. Cetera Investment Advisers now owns 59,273 shares of the company's stock worth $785,000 after buying an additional 7,574 shares in the last quarter. Institutional investors own 9.17% of the company's stock.

Wall Street Analyst Weigh In

Separately, Morgan Stanley raised Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research report on Wednesday, April 2nd.

Takeda Pharmaceutical Stock Performance

NYSE:TAK traded up $0.17 during trading on Friday, reaching $14.58. The company's stock had a trading volume of 1,991,062 shares, compared to its average volume of 1,929,161. The firm has a market cap of $46.38 billion, a price-to-earnings ratio of 36.44, a price-to-earnings-growth ratio of 0.24 and a beta of 0.26. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.72 and a current ratio of 1.31. The firm has a 50 day moving average of $14.69 and a 200-day moving average of $14.02. Takeda Pharmaceutical Company Limited has a 12 month low of $12.58 and a 12 month high of $15.43.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported $0.16 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.24 by ($0.08). The business had revenue of $7.34 billion during the quarter, compared to the consensus estimate of $8.02 billion. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. Research analysts expect that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current fiscal year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.